On April 7, 2023, KPMG China held the second "Biotechnology Innovation Top 50 Companies List" release and award ceremony simultaneously in Beijing, Shanghai, and Shenzhen offices, both online and offline. After rigorous selection and evaluation by an expert panel, Risen Pharma was selected for the "KPMG China Second Biotechnology Innovation Top 50 Companies List".

20

       The second "Biotechnology Innovation Top 50 Companies" is organized by KPMG China and co-organized by CITIC Securities Co., Ltd. Since its inception in 2021, it has received praise from the fields of scientific research, industry, investment, and enterprises. KPMG, together with more than ten internal and external authoritative experts, evaluates biopharmaceuticals, cell therapy, gene therapy, in vitro diagnostics, medical devices, and drug development companies in six major areas based on five core evaluation dimensions: team, technology, product, market, and financing. Using an open, fair, and impartial evaluation standard, the selected companies with potential for biotechnology innovation are chosen through on-site interviews and research by the judges. The aim is to jointly promote the high-quality and healthy development of the biotechnology innovation industry in China.

      The selection of Risen Pharma for the "KPMG China Second Biotechnology Innovation Top 50 Companies List" is a recognition of Risen Pharma's innovation capabilities and an encouragement for its development philosophy.

      Making significant contributions in the field of medical health, specifically in anti-aging and anti-tumor for humans, to make people healthier and live longer.

     Risen Pharma is an international competitive high-tech conglomerate that aims to prioritize patients and provide affordable and clinically needed original new molecular entity drugs. It has a complete capability ranging from drug lead molecule discovery and evaluation to new drug clinical development and commercialization. The company has two research and development centers, with a total area of nearly 9000 square meters, located in the core areas of Zhangjiang in Shanghai and Suzhou Industrial Park. It has also invested in the construction of an industrial base covering an area of 55 acres in the Lingang New Area Life Blue Bay. The group has a pipeline of nearly 20 new drug development projects, with a focus on the core treatment areas of orthopedics, oncology, and neuroscience. It also has dedicated research investment in the field of small nucleic acids, with several pipeline projects in clinical trial stages.